AstraZeneca Beats Mylan Challenge To Inhaler IP's Validity
AstraZeneca scored a win in a suit accusing Mylan Pharmaceuticals of infringing patents for its asthma treatment Symbicort when a West Virginia federal judge on Tuesday shot down arguments that the...To view the full article, register now.
Already a subscriber? Click here to view full article